2024-517429-24-00招募中2 期
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
PDC line pharma10 个研究点 分布在 5 个国家目标入组 64 人开始时间: 2024年10月29日最近更新:
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
- 试验地点
- 10
- 主要终点
- Occurrence of dose-limiting toxicities (DLT) related to the administration of PDC*lung01
研究概览
简要总结
Assess safety and tolerability of PDC*lung01 vaccinations administered at two dose levels as single agent or during maintenance treatment by pemetrexed (for adenocarcinomas in Cohorts A1 and A2) or during treatment with anti-PD-1 therapy (Cohorts B1 and B2).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized
- 主要目的
- Phase I/II
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Pre-screening: Documented HLA-A*02:01 positivity and absence of anti-HLA antibodies against HLA molecules expressed by the PDC*line (See protocol section 14.9.2), after the patient has provided written informed consent. Only patients meeting the above 2 criteria in pre-screening will be allowed to enter the screening period.
- •In the Investigator’s opinion, the patient is able and willing to comply with the requirements of the study
- •Patient willing and able to sign the study informed consent form before any study-specific procedures are conducted
- •Patient (male or female) is aged 18 years or above
- •Specific for patients enrolled in France: Patient is affiliated to a health insurance system
- •Patients with histologically proven, or cytologically proven, non-small-cell lung cancer (NSCLC). The stage of the disease is evaluated according to the classification of the American Joint Committee on Cancer, 8th edition (see protocol section 24.1) a. For the dose-escalation phase (Cohorts A1 and A2): a period of at least 4 weeks after last SOC treatment administration/standard therapeutic intervention is required before first study dose administration: (i) Stage IIa/IIb/IIIa NSCLC following radical surgery (R0 resection) and, if applicable, following adjuvant platinum-based chemotherapy, or (ii) Stage IV histologically or cytologically confirmed case of epidermoid (squamous) lung cancer following 4 courses of platinum-based therapy, if targeted treatment options were not indicated or (iii) Stage IV histologically or cytologically confirmed case of adenocarcinoma (non-squamous) lung cancer following 4 to 6 cycles of pemetrexed and platinum combination, if targeted treatment options were not indicated (iv) Populations (ii) and (iii) who have stopped prematurely chemotherapy, after at least 2 cycles of platinum-based therapy, for any reason, AND do present with a documented stable disease or partial / complete response. b. For the anti-PD-1 immunotherapy (Cohorts B1 and B2): The patient has first-line metastatic stage IV NSCLC measurable disease and is starting anti-PD-
- •The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%), assuming no targeted mutation detected, following standard NGS testing, if applicable, and thus no targeted treatment option is indicated, must have been made by the investigator before and regardless of the patient’s participation in the study. Radiotherapy/chemoradiotherapy for prior stage III NSCLC is allowed if the treatment-free interval is >1 year.
- •ECOG performance status 0 or 1
- •Adequate renal and hepatic function as defined below: Serum creatinine clearance > 50 mL/min (Cockcroft–Gault formula) • Bilirubin ≤ 1.5 times upper limit of normal (ULN) • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times ULN (up to 5 times ULN are allowed in case of presence of liver metastases)
- •Adequate haematological function as defined below: • Platelet count ≥ 70 × 109 /L; • White blood cell count ≥ 2.5 x 109 /L with lymphocytes ≥ 1 x 109 /L at screening or at baseline and absolute neutrophil count ≥ 1.5x109/L; • Haemoglobin ≥ 90 g/L
- •Patient willing to provide a baseline blood sample for leucocyte enumeration, cellular allogeneic response and immune-monitoring of 100 ml in total (in one or two samplings)
- •For patients with brain metastases: • Central nervous system metastases are not symptomatic or have been treated, • Subjects with symptomatic CNS metastases must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent) during at least 2 weeks before baseline
- •For female patients without child-bearing potential: a documentation of tubal ligation or hysterectomy, ovariectomy or a post-menopausal status is available. For female patients of child-bearing potential: a negative serum pregnancy test at screening is required. The patient agrees to use a highly effective contraception method from signing informed consent form (screening), throughout the study treatment period with PDC*lung01 and for at least 28 days after the last administration of PDC*lung
- •For female patients receiving Pemetrexed in cohorts A1/A2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use effective contraception during treatment with pemetrexed. For female patients receiving Pembrolizumab in cohorts B1/B2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use an effective method of contraception up to 4 months thereafter. A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. - “Highly effective” contraceptive measures acceptable for the whole duration of the study have been defined based on the CTFGs recommendations on contraception and are the following: − Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), − Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable). − Intrauterine device (IUD) − Intrauterine hormone-releasing system (IUS) − Monogamous relationship with a vasectomized partner. Partner must have been vasectomized for at least 6 months before the participant entered into the study - Abstinence or absence of sexual relations with men
- •Males with reproductive potential should use barrier method of contraception (condom) from signing informed consent form (screening) up to at least 28 days after the last dose of PDC*lung
- •For male patients receiving Pemetrexed in cohorts A1/A2 concomitantly with PDC*lung01, according to corresponding SmPC, it is required to use barrier method of contraception up to 6 months thereafter
排除标准
- •Mixed small-cell and non-small-cell histological features
- •Any history of splenectomy or splenic irradiation
- •For female patients: pregnancy or lactation
- •Any condition, including autoimmune or immunodeficiency active disease that, in the opinion of the Investigator, would jeopardise patient’s safety, or might compromise the effect of the study drug or the assessment of the study result. Patients with vitiligo, diabetes Type I, psoriasis (not requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, or oral corticosteroids within the previous 12 months) or a history of autoimmune thyroiditis are not excluded
- •Specific for patients enrolled in France: Patient is under legal protection
- •Patient has documented evidence of EGFR mutation, ALK fusion or ROS1 fusion (according to current ESMO clinical practice guidelines) or any mutation for which targeted treatment options would be indicated, as per SoC
- •Patient has received immunotherapy or any investigational drugs within 4 weeks before the first PDC*lung01 dose. Chemoradiotherapy with consolidation durvalumab for prior stage III disease
- •Patient with Stage IV disease that received prior radiotherapy (except palliative radiotherapy e.g. brain irradiation). Palliative radiotherapy for stage IV disease should be completed one week prior to baseline visit and for brain irradiation a 2-week window is required
- •Patient without brain metastasis is receiving systemic corticosteroids at a dose level exceeding 10 mg/day (prednisone or equivalent) during the screening period (administration by nasal spray, topical solution or oral inhaler is non-systemic and is therefore allowed)
- •Patient has a medical history of cancer other than NSCLC, except the following: (i) non-melanoma skin cancer with complete resection, (ii) adequately treated carcinoma in situ, (iii) other cancer treated with no evidence of disease for at least five years with the exception of pT1-2 prostatic cancer Gleason score < 6 and superficial bladder cancer
- •Known hepatitis B and/or C infection (testing not required)
- •Known positive for human immunodeficiency virus (HIV; testing not required)
- •Uncontrolled congestive heart failure or hypertension, unstable heart disease (coronary artery disease with unstable angina or myocardial infarction within 6 months of baseline) or uncontrolled ventricular arrhythmias at the time of enrolment in the study (atrial fibrillation or flutter is acceptable)
结局指标
主要结局
Occurrence of dose-limiting toxicities (DLT) related to the administration of PDC*lung01
Occurrence of dose-limiting toxicities (DLT) related to the administration of PDC*lung01
次要结局
- Occurrence of serious adverse events (SAEs) and adverse events (AEs), deemed as related to the association of PDC*lung01 and the anti-PD-1 therapy, monitored during study treatment until 28 days after the last dose of PDC*lung01
- Occurrence of serious adverse events (SAEs) and adverse events (AEs), monitored during study treatment until 28 days after the last dose of PDC*lung01
- Measurement of anti-HLA class I and II antibodies in the serum. In case of positive detection, the allelic specificity of the antibodies will be determined
- Ex vivo detection and characterization of CD8+ T cells against tumor antigens borne by PDC*lung01, using flow cytometry
- Objective Response Rate (according to RECIST version 1.1) for cohort B2
- Objective Response Rate (according to iRECIST) for cohort B2
- Progression-Free Survival at 9 months according to RECIST 1.1 and according to iRECIST from the first day of anti-PD-1 antibody administration for cohort B2
研究者
PDC*line Pharma Contact
Scientific
PDC line pharma
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-PLPDC*line Pharma SAS64
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-DEPDC*line Pharma SAS64
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCEUCTR2018-002382-19-NLPDC*line Pharma SAS70
进行中（未招募）
1 期
Safety, immunogenicity and preliminary clinical activity study of PDC*lung01 cancer vaccine in NSCLCon-small-cell lung cancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-002382-19-BEPDC*line Pharma SAS64
尚未招募
2 期
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)lung cancerNSCLCNL-OMON56303PDC*line Pharma SAS11